Pain Therapeutics (NASDAQ:PTIE) was downgraded by investment analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a note issued to investors on Friday.

Separately, Zacks Investment Research upgraded shares of Pain Therapeutics from a “hold” rating to a “buy” rating and set a $4.25 price objective for the company in a report on Tuesday, October 31st.

Pain Therapeutics (NASDAQ:PTIE) opened at $4.06 on Friday. Pain Therapeutics has a 12 month low of $3.10 and a 12 month high of $9.31.

Pain Therapeutics (NASDAQ:PTIE) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.40) EPS for the quarter. equities analysts anticipate that Pain Therapeutics will post -2.2 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in Pain Therapeutics stock. Dimensional Fund Advisors LP acquired a new position in Pain Therapeutics, Inc. (NASDAQ:PTIE) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 59,989 shares of the biopharmaceutical company’s stock, valued at approximately $247,000. Dimensional Fund Advisors LP owned about 0.91% of Pain Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 36.16% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/12/02/pain-therapeutics-ptie-lowered-to-strong-sell-at-valuengine.html.

About Pain Therapeutics

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Receive News & Stock Ratings for Pain Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics Inc. and related stocks with our FREE daily email newsletter.